Skip to Content

Dr. Jarrard's work in chemohormonal therapy for prostate cancer appears in New England Journal of Medicine

David F. Jarrard, MD, was part of a multicenter trial whose results were published in the August 20, 2015, New England Journal of Medicine (NEJM) article Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The study showed that administering six cycles of docetaxel at the beginning of androgen-deprivation therapy (ADT) resulted in significantly longer overall survival than ADT alone.

Dr. Jarrard says that for those men with high-volume, metastatic disease at the time of diagnosis, these findings are a “game changer.” “With respect to the treatment of their metastatic disease, combination chemohormonal therapy appears, on average, to extend their overall survival for at least a year compared to ADT alone,” he adds. Copyright © 2017 The Board of Regents of the University of Wisconsin System